Loading
A blinded three-hospital study found that men with the shortened receptor in their circulating tumour cells lived roughly twice as long on chemotherapy as on another hormone tablet, and that men without it did better the other way round.
A blinded correlative study conducted between December 2012 and September 2016 included 142 men with histologically confirmed metastatic castration-resistant prostate cancer treated at Memorial Sloan Kettering Cancer Center, the Royal Marsden or the London Health Sciences Centre. Blood samples were taken before an androgen receptor signalling inhibitor or a taxane given as second-line or later therapy for progressing disease, and nuclear-localised AR-V7 protein in circulating tumour cells was measured on a validated assay. Among the 70 men designated high risk by conventional prognostic factors, AR-V7-positive men treated with taxanes had a median overall survival of 14.3 months against 7.3 months for those treated with receptor signalling inhibitors (hazard ratio 0.62), while AR-V7-negative men treated with receptor signalling inhibitors had a median overall survival of 19.8 months against 12.8 months on taxanes (hazard ratio 1.67).
It is the clearest evidence in prostate cancer that a blood biomarker can point to one treatment class over another, and the reason AR-V7 is discussed in guidelines despite being in no label.
Shares AR-V7 splice variant, AR-V7 splice variant, RNA splicing, Intravasation & circulating tumour cells.
Shares AR-V7 splice variant, AR-V7 splice variant, RNA splicing, Intravasation & circulating tumour cells.
Shares AR-V7 splice variant, Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired).
Shares Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired), Androgen receptor.
Shares AR-V7 splice variant, Castration-resistant prostate cancer (CRPC), Androgen receptor, Metastatic castration-resistant prostate cancer.
Shares Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired), Androgen receptor.
Shares Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired), Androgen receptor.
Shares AR-V7 splice variant, Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired).